Pemetrexed Injection 500 mg

Pemetrexed Injection 500 mg is used  for the treatment of malignant pleural mesothelioma in patients whose disease is unresectable or who are otherwise not candidates for curative surgery (In combination with cisplatin); as a single agent for the initial treatment of locally advanced or metastatic non–small cell lung cancer after prior chemotherapy; in combination with cisplatin for the treatment of locally advanced or metastatic nonsquamous non–small cell lung cancer; for the maintenance treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy.

3s corporation is Supplier,Exporter ,Wholesaler  for Pemetrexed Injection 500 mg in India.

We even  offer contract manufacturing services from WHO GMP approved factories.

IV Recommended dose is 500 mg/m 2 infused over 10 min on day 1 of each 21-day cycle.


Supraventricular arrhythmia (less than 1%).


Fatigue (34%); sensory neuropathy (9%); motor neuropathy (1% to 5%).


Rash/desquamation (14%); pruritus (7%); alopecia (6%); erythema multiforme (1% to 5%).


Increased lacrimation, ocular surface disease including conjunctivitis (1% to 5%).


Nausea (31%); anorexia (22%); vomiting (16%); stomatitis/pharyngitis (15%); diarrhea (13%); mucositis/stomatitis (7%); constipation (6%); abdominal pain (1% to 5%); colitis (postmarketing).


CrCl decreased, creatinine increased, glomerular filtration rate decreased (1% to 5%); renal failure (less than 1%).


Anemia (19%); leukopenia (12%); neutropenia (11%); thrombocytopenia (8%); febrile neutropenia (1% to 5%).


Increased ALT (10%); increased AST (8%).


Allergic reactions/hypersensitivity (1% to 5%).


Interstitial pneumonitis (postmarketing).


Fever (8%); infection (5%); edema (1% to 5%); radiation recall (postmarketing).